These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35262108)

  • 21. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel metals and metal complexes as platforms for cancer therapy.
    Frezza M; Hindo S; Chen D; Davenport A; Schmitt S; Tomco D; Dou QP
    Curr Pharm Des; 2010 Jun; 16(16):1813-25. PubMed ID: 20337575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics.
    Griffith D; Parker JP; Marmion CJ
    Anticancer Agents Med Chem; 2010 Jun; 10(5):354-70. PubMed ID: 20380633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks.
    Petanidis S; Kioseoglou E; Salifoglou A
    Curr Med Chem; 2019; 26(4):607-623. PubMed ID: 29149832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum.
    Gaynor D; Griffith DM
    Dalton Trans; 2012 Nov; 41(43):13239-57. PubMed ID: 22930130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.
    Leon IE; Cadavid-Vargas JF; Di Virgilio AL; Etcheverry SB
    Curr Med Chem; 2017; 24(2):112-148. PubMed ID: 27554807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metal-containing drugs and novel coordination complexes in therapeutic anticancer applications--part II.
    Kostova I
    Anticancer Agents Med Chem; 2010 Jun; 10(5):352-3. PubMed ID: 20545617
    [No Abstract]   [Full Text] [Related]  

  • 30. NSAID-Based Coordination Compounds for Biomedical Applications: Recent Advances and Developments.
    Santos ACF; Monteiro LPG; Gomes ACC; Martel F; Santos TM; Ferreira BJML
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods to identify protein targets of metal-based drugs.
    Skos L; Borutzki Y; Gerner C; Meier-Menches SM
    Curr Opin Chem Biol; 2023 Apr; 73():102257. PubMed ID: 36599256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smart cancer nanomedicine.
    van der Meel R; Sulheim E; Shi Y; Kiessling F; Mulder WJM; Lammers T
    Nat Nanotechnol; 2019 Nov; 14(11):1007-1017. PubMed ID: 31695150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metallodrugs as Anticancer Chemotherapeutics and Diagnostic Agents: A Critical Patent Review (2010-2020).
    Fotopoulou E; Titilas I; Ronconi L
    Recent Pat Anticancer Drug Discov; 2022; 17(1):42-54. PubMed ID: 34493191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Nanomedicines in an Evolving Oncology Landscape.
    Guo P; Huang J; Moses MA
    Trends Pharmacol Sci; 2020 Oct; 41(10):730-742. PubMed ID: 32873407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
    Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
    Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent development of transition metal complexes with in vivo antitumor activity.
    Liang JX; Zhong HJ; Yang G; Vellaisamy K; Ma DL; Leung CH
    J Inorg Biochem; 2017 Dec; 177():276-286. PubMed ID: 28641893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular Catalysis with Selected Metal Complexes and Metallic Nanoparticles: Advances toward the Development of Catalytic Metallodrugs.
    Soldevila-Barreda JJ; Metzler-Nolte N
    Chem Rev; 2019 Jan; 119(2):829-869. PubMed ID: 30618246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifunctional Cargo-Free Nanomedicine for Cancer Therapy.
    Wang Y; Yang P; Zhao X; Gao D; Sun N; Tian Z; Ma T; Yang Z
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Structural Chemistry Perspective on the Antimalarial Properties of Thiosemicarbazone Metal Complexes.
    Summers KL
    Mini Rev Med Chem; 2019; 19(7):569-590. PubMed ID: 30324878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.